Gallagher Fiduciary Advisors, LLC Beam Therapeutics Inc. Transaction History
Gallagher Fiduciary Advisors, LLC
- $485 Million
- Q4 2024
A detailed history of Gallagher Fiduciary Advisors, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Gallagher Fiduciary Advisors, LLC holds 9,220 shares of BEAM stock, worth $180,066. This represents 0.05% of its overall portfolio holdings.
Number of Shares
9,220Holding current value
$180,066% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding BEAM
# of Institutions
251Shares Held
78.5MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$161 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$149 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$149 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$138 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$88.7 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.37B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...